Relsys' suite of applications collects, monitors and analyzes safety data during all processes of developing and implementing new medications, biologics and medical devices, according to the vendors. This enables earlier detection of risks in the development cycle, and of pre- and post-market safety issues.
Relsys serves more than 100 customers. They include five of the top 10 pharmaceutical firms, seven of the top 15 biotech firms, four of the top 10 clinical research organizations and four of the top 10 medical device manufacturers.
The companies expect the acquisition to close during the first half of 2009. Relsys will become part of Redwood Shores, Calif.-based Oracle's Health Sciences Global Business Unit. Oracle's stock rose nearly 7% on March 23 after the acquisition was announced.
More information is available at relsys.net and oracle.com.
This article can also be found at HealthDataManagement.com.
This piece is brought to you by the editorial staff of SourceMedia.
Be the first to comment on this post using the section below.